COSA:NETs guidelines/Liver directed therapies

From Cancer Guidelines Wiki
Cosa prev button.png
Cosa overview button.png
Cosa next button.png

NETs banner new.png



Liver directed therapies

Indications for liver directed therapies

One of the major prognostic factors that dramatically affects survival in patients with NETs is the presence of liver metastases. Unfortunately, liver metastases are common in patients with NETs. Key point: up to 75% of patients who present with NETs also have liver metastases. Furthermore, NET liver metastases that are either extensive or progressing are adverse prognostic factors.

Liver directed therapies may be contra-indicated by pre-existing hepatic insufficiency, or if this can be predicted to be likely following therapy. Selection of patients must be based on a combination of morphologic and functional imaging to establish the presence and extent of extra-hepatic disease. Unlike colorectal cancer where presence of unresectable extra-hepatic metastases generally contraindicates surgical resection of liver metastases, palliative hepatic resection in NETs may be considered in the context of multi-modality treatment paradigms.

For these reasons, the optimal management of patients with NET liver metastases should involve evaluation in a multi-disciplinary environment with access to advanced imaging techniques, interventional radiology, surgical and medical expertise.

The options available can be categorised as follows:

  • Surgical
  • Medical (e.g. somatostatin analogues, chemotherapy)
  • Targeted nuclear medicine (e.g. peptide receptor radionuclide therapy)
  • Interventional radiological
  • If debulking of liver metastases is under consideration, other liver directed therapies and/or systemic therapies in addition to surgery may also be considered.


Liver therapies.jpg

Back to top

Treatment approaches to NET liver metastases

The treatment approach to patients with NET liver metastases is dictated, naturally, by the pattern of disease within the liver. Morphologically, there are three different patterns of liver metastases:

Treatment approach to liver metastases without extra-hepatic spread

A. Simple Pattern: The metastases are confined to one liver lobe or limited to two adjacent segments so that they can be resected by a standard anatomical resection. This “simple pattern” occurs in 20 – 25% of the cases. These patients are treated with: (i) Surgery – minor or anatomical resection or (ii) Liver directed therapy if not fit for surgery.

B. Complex Pattern: There is one major lesion but with smaller satellite lesions contra-laterally. This “complex bi-lobar pattern” occurs in 10 – 15% of the cases. These patients are treated with: (i) Surgery – major one-step or two-step (i.e. sequential) resection. Prior to resection, portal vein embolisation can be performed to increase the size of the functional liver remnant (FLR). (ii) Liver directed therapy if not fit for surgery.

C. Diffuse Pattern: There are diffuse, multifocal liver metastases. This “diffuse pattern” occurs in 60 – 70% of the cases. These patients are unresectable and are thus treated with: (i) Liver directed therapy.


Figure 1: Treatment approach to liver metastases without extra-hepatic spread. Treatment approach.jpg


The first line of therapy in limited “simple pattern” (uni-lobar) and “complex pattern” (bi-lobar) liver metastases without extra-hepatic spread is surgical resection with or without liver directed therapy techniques. Patients with “diffuse pattern” liver metastases, and those who are poor surgical candidates, may be treated with biotherapy, chemotherapy, or liver directed therapy.


LM = liver metastasis; RFA = radiofrequency ablation; RPVE = right portal vein embolization; RPVL = right portal vein ligation; LITT = laser-induced thermotherapy; RE = radio-embolization; TACE = trans-catheter arterial chemoembolization; TAE = trans-catheter arterial embolization.

Back to top

Treatment approach to liver metastases with extra-hepatic spread

Figure 2: Treatment approach to liver metastases with extra-hepatic spread.

Treatment approach liver metastases with extra-hepatic spread.jpg


Patients with liver metastases with inoperable extra-hepatic spread should initially be treated using non-surgical methods (biotherapy, chemotherapy, etc) regardless of the extent of liver disease. If palliative steps are also required, liver directed therapy may be used in “simple pattern”, “complex pattern” and “diffuse pattern” liver metastases. Surgery (of a debulking nature) may be undertaken for selected candidates.

Back to top

Surgery

Key point: Surgical resection remains the gold standard in the treatment of NET liver metastases, achieving a survival rate of 60 – 80% at 5 years with low mortality (0 – 5%) and acceptable morbidity (close to 30%). The minimal requirements for resection with “curative intent” are the following:

  • Resectable well-differentiated liver metastases with acceptable morbidity and < 5% mortality
  • Absence of right heart insufficiency
  • Absence of extra-abdominal metastases
  • Absence of diffuse peritoneal carcinomatosis.


In planning the operation, care should be taken to assess the amount and quality of the postoperative remnant liver parenchyma. In both synchronous and metachronous tumours, one- and two-step procedures may be undertaken, depending upon whether the liver disease is “simple pattern” (uni-lobar) or “complex pattern” (bi-lobar).

Debulking resections can be justified in exceptional palliative situations, however removal of at least 90% of the tumour volume is necessary. If the primary tumour is still present, it should be removed at this time as well.[1]

Back to top

Liver Transplantation

In patients with “diffuse pattern” unresectable liver metastases or who suffer from life-threatening hormonal disturbances refractory to medical therapy, liver transplantation has been considered as a treatment option for highly selected candidates. However at the present time it cannot be recommended as routine practice. See "Liver Transplantation" in the Surgery section of these guidelines for further information.

Key point: A long-term cure from the disease by transplantation will be an exceptional event even in this highly selected subgroup.

Back to top

Ablative techniques

Ablative techniques such as RFA can be used effectively as anti-tumour treatment and in relieving symptoms in patients with NET liver metastases, either as a sole therapy or in combination with surgery.[2][3][4][5]

While surgery remains the therapy of choice in limited metastatic disease, RFA may be employed for palliation in order to avoid a major surgical procedure and it can also effectively supplement a surgical resection. In patients with tumours > 5 cm in diameter or near vital structures, RFA or other ablative techniques are not the most suitable single therapy.[6][7][8][9]

Back to top

TACE

Selective hepatic trans-catheter arterial embolization (TAE) or chemo-embolization (TACE) may be used to treat liver metastases in patients where surgery is not feasible regardless of the origin of the primary tumour.[10][11][12]

Key point: These modalities are effective in controlling symptoms and tumour growth and result in significant decrease in biochemical markers with objective tumour responses in about 50% of patients. No current evidence exists that TACE is superior to TAE.[13][14]

The cytotoxic agents used include either doxorubicin or streptozotocin in a mixture with lipiodol. Because of their potential morbidity, TAE or TACE should be performed in experienced centres. A common side effect is post-embolization syndrome (presenting as pain, low grade fever, nausea and general malaise with little change in blood biochemistry usually lasting 3 days), but major side effects are rare.[15][16]

The procedures are contra-indicated in the case of complete portal vein thrombosis and hepatic insufficiency. In patients in whom liver transplantation may subsequently be considered, multiple TAE or TACE can induce endoarteritis rendering the vascular reconstruction at transplantation more difficult due to arterial thrombosis.[17][18]

Back to top

Drug Eluting Beads (DEB)

Selective hepatic trans-catheter arterial chemo-embolization with drug eluting beads (DEB) or low density beads (also known as “precision TACE”) may be used to treat liver metastases in patients where surgery is not feasible regardless of the origin of the primary tumour.[19]

These modalities should be as effective as conventional TACE in controlling symptoms and tumour growth and result in significant decrease in biochemical markers with objective tumour responses.[20]

No current evidence exists that DEB is superior to conventional TACE. The cytotoxic agents used include either doxorubicin or irinotecan. Because of its potential morbidity DEB should be performed in experienced centres. Similar to conventional TACE, a common side effect is post-embolization syndrome. Major side effects are rare and the same as for conventional TACE, with a possibly higher incidence of hepatic abscess formation.[21]

The procedure is contra-indicated in the case of complete portal vein thrombosis and hepatic insufficiency. In patients in whom liver transplantation may subsequently be considered, multiple treatments can induce endoarteritis rendering the vascular reconstruction at transplantation more difficult due to arterial thrombosis.[22]

Back to top

Radio-embolization (SIRT)

Selective internal radiation therapy (SIRT), also known as radio-embolization (RE) or microbrachytherapy, may be used to treat liver metastases in patients where surgery is not feasible regardless of the origin of the primary tumour.[23]

Key point: This modality is effective in controlling symptoms and tumour growth and results in significant decrease in biochemical markers in patients with objective tumour responses.

While no current evidence exists that RE is superior to TACE, the US equivalent of ENETS the North American Neuroendocrine Tumour Society (NANETS), as announced in 2010, recommends radio-embolisation as a liver directed therapy in preference to TACE and TAE.[24][25]

Post-embolization syndrome is less common and less pronounced in patients undergoing RE compared to TACE and major side effects are rare in experienced institutions. RE is contra-indicated in the case of complete portal vein thrombosis, hepatic insufficiency, excessive lung shunting (as determined by Tc-99 MAA lung shunt study) and where non-targeted flow to the stomach or small bowel cannot be corrected by coil embolisation techniques.[26][27]

Increasing clinical data are becoming available from clinical trials on the safety and efficacy of RE in the management of NET liver metastases.[28]


Figure 3: Summary of clinical data on RE in NET liver metastases. Summary of clinical data on RE in NET liver metastases.jpg

Back to top

Potential advantages of radio-embolization over other liver directed therapies

A. Higher complete response rate of up to 18%:

  • King, Morris et al.[29] found that:
    • Some patients achieved complete response (CR) in the liver after RE for ≥ 2 years.
    • Although CR can occur after TAE alone, it is very uncommon; whereas CR was observed in 6 of 34 patients after RE treatment.
    • Patients who achieved a CR in their liver survived from 26 – 48 months.
  • Saxena, Bester et al.[30] found that:
    • Their data demonstrated efficiency of treatment with 15% of patients showing a CR and a futher 40% a PR with median survival of 35 months and a three year survival of 46%.


B. Lower treatment related morbidity:

  • Lower treatment related morbidity from RE compared to TACE or TAE, thus is typically associated with less hospitalization and more rapid return to normal daily activities.[31][32]


C. SIRT may allow subsequent TACE, but TACE may rule out subsequent SIRT:

  • Due to smaller size of RE microspheres (25 – 35 microns), these particles embolize more distally, in the tumour vascular bed and do not destroy main and segmental hepatic arteries. This means that if disease progresses after RE, then TACE or TAE may still be used.
  • On the other hand TACE and TAE destroy the main and segmental hepatic arteries, thus preventing the subsequent use of RE in the event of tumour progression.

Back to top

Therapy choice

In the absence of evidence comparing them, these guidelines currently support the use of either TACE or SIRT as local regional therapies for this disease – acknowledging availability and cost issues. There seems to be therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma.[33]

The long-term complications of SIRT are yet to be established.

The use of DC beads outside clinical trials is not recommended, given many reports of complications.

The algorithm needs to clarify when these interventions need to be considered.

Back to top

Sequential use of SIRs and PRRT

There is some concern about using PRRT after SIRs, but not the converse. The main theoretical issue is that a reduction in the regional delivery of the peptide to tumour deposits by virtue of radiation endarteritis, internal radiation fibrosis and reduced numbers of a viable, somatostatin-receptor expressing cells following SIRT may reduce the efficacy of PRRT, rather than major concerns regarding toxicity to normal hepatic parenchyma as a result of the combination of therapies. Based on limited experience of patients who have received both therapies, there is no contraindication to using these approaches as guided by the underlying principles to their use. Ideally, a reasonable interval of time (months) should separate the therapies to allow regeneration of normal liver function.

The number of treatments the liver can tolerate and the risk of cumulative damage is yet to be established.

If after treatment with SIRs there is evidence of hepatic toxicity, clinician considering PRRT should proceed with caution.

Back to top

Radionuclide therapy

The systemic use of peptide receptor radionuclide therapy and I-131 MIBG therapy is dealt with elsewhere in these consensus guidelines. These therapies are suitable for patients with unresectable hepatic metastases even in the absence of extra-hepatic disease but in cases where there is dominant or exclusive involvement of the liver, consideration can be given to intra-arterial administration of either of these agents. Preliminary data using quantitative comparison of tracer uptake in NET lesions on PET/CT following intravenous versus intra-arterial Ga-68 DOTA-octreotate administration suggest that substantially higher dose can be achieved to lesions compared to other organs, including normal hepatic parenchyma, with direct intra-arterial administration.[34] Similar data are available for the use of intra-arterial I-131 MIBG.[35]

Back to top

References

  1. Steinmüller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008;87(1):47-62 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/18097131].
  2. Siperstein AE, Rogers SJ, Hansen PD, Gitomirsky A. Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases. Surgery 1997 Dec;122(6):1147-54; discussion 1154-5 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/9426432].
  3. Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 2001 Jun;25(6):693-6 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/11376399].
  4. Gillams A, Cassoni A, Conway G, Lees W. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging 2005 Jul;30(4):435-41 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/15759207].
  5. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Ierace T, Solbiati L, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 2000 Mar;214(3):761-8 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/10715043].
  6. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004 Jun;239(6):818-25; discussion 825-7 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/15166961].
  7. Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 2006 May;141(5):460-6; discussion 466-7 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/16702517].
  8. McKay A, Dixon E, Taylor M. Current role of radiofrequency ablation for the treatment of colorectal liver metastases. Br J Surg 2006 Oct;93(10):1192-201 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/16983740].
  9. Sutherland LM, Williams JA, Padbury RT, Gotley DC, Stokes B, Maddern GJ. Radiofrequency ablation of liver tumors: a systematic review. Arch Surg 2006 Feb;141(2):181-90 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/16490897].
  10. Mitty HA, Warner RR, Newman LH, Train JS, Parnes IH. Control of carcinoid syndrome with hepatic artery embolization. Radiology 1985 Jun;155(3):623-6 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/4001362].
  11. Roche A, Girish BV, de Baère T, Baudin E, Boige V, Elias D, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003 Jan;13(1):136-40 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/12541121].
  12. Marrache F, Vullierme MP, Roy C, El Assoued Y, Couvelard A, O'Toole D, et al. Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours. Br J Cancer 2007 Jan 15;96(1):49-55 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/17164755].
  13. Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993 Apr 15;71(8):2624-30 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/8384072].
  14. Therasse E, Breittmayer F, Roche A, De Baere T, Indushekar S, Ducreux M, et al. Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 1993 Nov;189(2):541-7 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/7692465].
  15. Perry LJ, Stuart K, Stokes KR, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 1994 Dec;116(6):1111-6; discussion 1116-7 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/7985095].
  16. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009 Aug;9(8):1920-8 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/19552767].
  17. Clouse ME, Perry L, Stuart K, Stokes KR. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 1994;55 Suppl 3:92-7 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/7698544].
  18. Diaco DS, Hajarizadeh H, Mueller CR, Fletcher WS, Pommier RF, Woltering EA. Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization. Am J Surg 1995 May;169(5):523-8 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/7747834].
  19. Del Poggio P, Maddeo A, Zabbialini G, Pitì A. Chemoembolization of hepatocellular carcinoma with drug eluting beads. J Hepatol 2007 Jul;47(1):157-8; author reply 159 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/17509721].
  20. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007 Mar;46(3):474-81 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/17239480].
  21. de Baere T, Deschamps F, Teriitheau C, Rao P, Conengrapht K, Schlumberger M, et al. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 2008 Jun;19(6):855-61 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/18503899].
  22. Lencioni R. TACE in HCC: a multi-disciplinary overview. Presentation at Society of Interventional Radiology; 2008 [cited 2014 Jun 12].
  23. Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008 Jun;31(3):271-9 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/18525307].
  24. King J, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008 Sep 1;113(5):921-9 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/18618495].
  25. Meranze SG, Bream PR, Grzeszczak E, et al. Phase II clinical trial of yttrium-90 resin microspheres for the treatment of metastatic neuroendocrine tumor. Society of Interventional Radiology; 2007 [cited 2014 Jun 12]. Report No.: Abstract 422.
  26. Wagner J. Pilot study of SIR-Spheres in neuroendocrine tumors liver metastases. 2nd european symposium on liver-directed cancer therapies using microspheres. Rome, Italy; 2008 Feb [cited 2014 Jun 12].
  27. Kennedy A, Dezarn W, McNeillie P, Overton C, England M, Sailer SL. Fractionation, dose selection, and response of hepatic metastases of neuroendocrine tumors after 90Y-microsphere brachytherapy. ABS 2006 [cited 2014 Jun 12];5(2):103 [Abstract available at http://www.brachyjournal.com/article/S1538-4721(06)00128-0/abstract].
  28. Murthy R, Kamat P, Nunez R, Madoff DC, Gupta S, Salem R, et al. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol 2008 Jan;19(1):145-51 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/18192482].
  29. King J, Morris D, Glenn D, et al. SIR-Spheres for liver metastases from neuroendocrine tumours. Australia: World Congress of Gastrointestinal Cancer; 2005 [cited 2014 Jun 12]. Report No.: Abstract P-090. Available from: http://www.radmed.com.tr/usr_img/sir_spheres/pdf/sirspheresin_neuroendocrinetumours.pdf.
  30. Saxena A, Chua TC, Bester L, Kokandi A, Morris DL. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg 2010 May;251(5):910-6 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/20395859].
  31. Kalinowski M, Dressler M, König A, El-Sheik M, Rinke A, Höffken H, et al. Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion 2009;79(3):137-42 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/19307736].
  32. Cao C, Yan T, Bester L, Liauw W, Morris DL. Sir-spheres for NETLMs – A Bi-Institutional Study on Treatment Response and Survival. Br J Radiol 2009 [cited 2014 Jun 12];In Press.
  33. Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 2010 Mar 1;116(5):1305-14 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/20066715].
  34. Beauregard JM, Eu P, Neels O, Hicks RJ. Enhanced uptake in neuroendocrine tumours after intraarterial infusion of [68Ga]/[177Lu]-octreotate. EJNMMI 2009 [cited 2014 Jun 12];36(Suppl 2):S278.
  35. Popp M, Strumpf A, Zöphel K, Stroszczynski C, Kotzerke J. Increased uptake of (131)I-MIBG after intra-arterial application in liver metastases of a neuroendocrine tumor. Eur J Nucl Med Mol Imaging 2010 Jan;37(1):180 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/19789869].

Back to top

Cosa prev button.png
Cosa overview button.png
Cosa next button.png